Adverse effects include muscle damage known as myopathy, including a severe form known as rhabdomyolysis; proteinuria or protein in the urine; nephropathy, a reduced ability of the kidneys to filter toxins from the blood; and kidney failure.
Dr. Richard Karas of the Tuft-New England Medical Center in Boston, who led the study, said his team found a rate of 28 adverse events per million prescriptions of Crestor, known generically as rosuvastatin.
Karas said there were 6 per million deaths on Crestor as compared to 3 per million for Zocor, 1 per million with Bristol Myers Squibb's Pravachol and 2 per million for Lipitor.
In March, the FDA denied a petition by the consumer group Public Citizen to ban Crestor, saying it disagreed with arguments that Crestor was more dangerous than other statins.
Journal Circulation, Courtesy of Reuters 5/23/2005
No comments:
Post a Comment